Revenue (Quarterly) Chart

View Revenue (Quarterly) for XGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue (Quarterly) Chart
Start Trial

Historical Revenue (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 19.94M
March 31, 2026 17.31M
December 31, 2025 16.63M
September 30, 2025 17.24M
June 30, 2025 17.20M
March 31, 2025 15.50M
December 31, 2024 13.66M
September 30, 2024 12.51M
June 30, 2024 15.06M
March 31, 2024 14.42M
December 31, 2023 13.76M
September 30, 2023 13.42M
June 30, 2023 14.14M
March 31, 2023 11.23M
December 31, 2022 12.84M
September 30, 2022 14.73M
June 30, 2022 7.606M
March 31, 2022 10.39M
December 31, 2021 12.69M
September 30, 2021 12.25M
June 30, 2021 12.77M
March 31, 2021 10.59M
December 31, 2020 12.67M
Date Value
September 30, 2020 10.78M
June 30, 2020 8.948M
March 31, 2020 9.584M
December 31, 2019 10.21M
September 30, 2019 10.44M
June 30, 2019 10.47M
March 31, 2019 9.26M
December 31, 2018 9.641M
September 30, 2018 8.223M
June 30, 2018 7.781M
March 31, 2018 6.795M
December 31, 2015 4.449M
September 30, 2015 4.66M
June 30, 2015 4.469M
March 31, 2015 4.368M
December 31, 2014 4.238M
September 30, 2014 3.672M
June 30, 2014 2.357M
March 31, 2014 1.396M
December 31, 2013 1.093M
September 30, 2013 0.935M
June 30, 2013 0.664M
March 31, 2013 0.363M

Revenues Definition

Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.

Read full definition.

Revenue (Quarterly) Range, Past 5 Years

View Revenue (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue (Quarterly) Benchmarks

View Revenue (Quarterly) Benchmarks
Start Trial
Myriad Genetics, Inc. 190.70M
BioRestorative Therapies, Inc. 0.0232M
CareDx, Inc. 131.95M
Natera, Inc. 752.75M
Sera Prognostics, Inc. 0.03M